{"Clinical Trial ID": "NCT00258960", "Intervention": ["INTERVENTION 1:", "Caelyx,Cyclophosphamide,Trastuzumab", "Caelyx (Doxorubicin liposomal) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab every 24 weeks for 2 mg/kg (charge dose of 4 mg/kg at day 1)", "Doxorubicin liposomal", "- Cyclophosphamide", "- Trastuzumab"], "Eligibility": ["Incorporation criteria:", "Patients must sign informed consent before using specific clinical trial procedures.", "Patients with histology-confirmed breast cancer and an overexpression of Her2neu.", "Age > 18 years.", "Eastern Cooperative Oncology Group (ECOG) equal to or < 2.", "Patients were not previously treated with chemotherapy for metastatic disease.", "Patients should have at least one measurable injury according to the RECIST criteria.", "Patients should have adequate organic function to tolerate chemotherapy.", "- Exclusion criteria:", "Patients with hypersensitivity reactions to any of the clinical trial medicinal products.", "Pregnant or lactating patients are not eligible.", "- Hepatic disease.", "- Uncontrolled active infection", "- Symptomatic metastatic brain cancer", "Previous adjuvant treatment with anthracyclines with a total cumulative dose > 300 mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)"], "Results": ["Performance measures:", "Objective response rate (ORR)", "The ORR is the sum of the complete (CR) and partial (PR) responses according to the RECIST criteria, tested for each patient during treatment (recorded from the start of treatment to the progression of the disease).By criteria for assessing response in solid tumours (RECIST v1.0) for target lesions evaluated by the scanner (calculated tomography) or MRI (magnetic resonance imaging): complete response (CR), disappearance of all target lesions; partial response (PR), >=30% decrease in sum of the longest diameter of target lesions; overall response rate (ORR) = CR + PR.", "Time limit: Up to cycle 6 (24 weeks)", "Results 1:", "Title of the arm/group: Caelyx,Cyclophosphamide,Trastuzumab", "Description of the arm/group: Caelyx (Doxorubicin liposomal) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab every 24 weeks for 2 mg/kg (charge dose of 4 mg/kg at day 1)", "Doxorubicin liposomal", "- Cyclophosphamide", "- Trastuzumab", "Total number of participants analysed: 48", "Type of measure: Number of participants", "Unit of measure: Participants 33 68.8%"], "Adverse Events": ["Undesirable Events 1:", "Total: 16/48 (33.33 per cent)", "\u2022 Febrile neutropenia grade 3 3/48 (6.25 per cent)", "Neutropenia grade 3 1/48 (2.08%)", "1/48 (2.08%)", "Grade 3 hypersensitivity reaction 2/48 (4.17%)", "\u25ba erythrodysaesthesia palmoplantar grade 3, stomatitis grade 3 1/48 (2.08%)", "\u2022 Neutropenia grade 4, fever grade 1, mucous membrane grade 3 1/48 (2.08%)", "Catheter - Grade 3 bound infection 1/48 (2.08%)"]}